COMPOSITION FOR PREVENTING OR TREATING LUPUS, COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN

• Main Author: SONG, David
• Format: Patent
• Language: English; French; Korean
• Published: 07.03.2024
• Subjects: FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The present invention relates to a composition for preventing or treating lupus or glomerulonephritis, comprising a recombinant stabilized galectin 9 protein. Specifically, it was confirmed that the recombinant stabilized galectin 9 protein of the present invention shows safety in a systemic lupus erythematosus (SLE) animal model, reduces skin lesions, lymphadenopathy, and proteinuria caused by lupus, alleviates lupus nephritis and glomerulonephritis, and shows the effect of reducing the concentration of anti-dsDNA antibodies in plasma. Therefore, the recombinant stabilized galectin 9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis. La présente invention concerne une composition pour prévenir ou traiter le lupus ou la glomérulonéphrite, comprenant une protéine galectine 9 stabilisée recombinante. Plus précisément, il a été confirmé que la protéine galectine 9 stabilisée recombinante de la présente invention indique une sécurité dans un modèle animal de lupus érythémateux systémique (SLE), réduit les lésions cutanées, la lymphadénopathie et la protéinurie provoquées par le lupus, atténue la néphrite lupique et la glomérulonéphrite, et présente l'effet de réduction de la concentration d'anticorps anti-ADNdb dans le plasma. Par conséquent, la protéine de galectine 9 stabilisée recombinante de la présente invention peut être efficacement utilisée en tant que principe actif dans une composition pour prévenir ou traiter le lupus ou la glomérulonéphrite. 본 발명은 재조합 안정화 갈렉틴 9 단백질을 포함하는 루푸스 또는 사구체신염 예방 또는 치료용 조성물에 관한 것으로, 구체적으로 본 발명의 재조합 안정화 갈렉틴 9 단백질이 전신 홍반성 루푸스(systemic lupus erythematosus; SLE) 동물모델에서 안전성을 나타내고, 루푸스에 의한 피부 병변, 임파선 종대 및 단백뇨를 감소시키며, 루푸스신염 및 사구체신염을 완화하고, 혈장 내 항-dsDNA 항체 농도를 감소시키는 효과를 나타냄을 확인하였으므로, 본 발명의 재조합 안정화 갈렉틴 9 단백질은 루푸스 또는 사구체신염 예방 또는 치료용 조성물의 유효성분으로 유용하게 사용될 수 있다.